ReviewJournal of biochemical and molecular toxicology2026
Proteomic Biomarker Discovery in Breast Cancer: Advances, Challenges, and Translational Prospects.
Review in Journal of biochemical and molecular toxicology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer remains a leading cause of cancer-related morbidity and mortality among women worldwide. Despite major progress in genomic classification, molecular pathology, and targeted therapy, the identification of clinically reliable proteomics-derived biomarkers for early detection, prognostic stratification, treatment response prediction, and longitudinal monitoring remains an unresolved translational challenge. Recent studies have applied proteomic profiling to breast cancer tissues and clinically accessible biofluids, including serum, plasma, saliva, nipple aspirate fluid, urine, and extracellular vesicle-enriched fractions, to identify protein signatures with potential diagnostic and therapeutic relevance. Contemporary platforms, including LC-MS/MS, data-independent acquisition mass spectrometry, multiplexed quantitative proteomics, targeted proteomics using multiple reaction monitoring and parallel reaction monitoring, spatial proteomics, and affinity-based high-throughput assays such as Olink and SomaScan, have expanded the analytical depth and clinical scalability of breast cancer biomarker research. However, many candidate biomarkers remain confined to discovery or early verification stages because of limited analytical sensitivity, insufficient specificity, inter-platform variability, small and heterogeneous cohorts, incomplete external validation, and uncertainty regarding clinical utility beyond established pathological markers. This review critically evaluates current proteomic technologies and proteomics-derived biomarker candidates in breast cancer, distinguishes discovery-level findings from clinically validated evidence, and discusses the major methodological, regulatory, and implementation barriers that continue to limit translation into routine oncology practice. Greater emphasis on standardized workflows, targeted verification, multi-center validation, and clinically actionable biomarker panels will be essential for integrating proteomics into precision breast cancer care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.